Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: Quo vadis?

Drug Discovery Today

Volumn 19, Issue 10, 2014, Pages 1623-1631

  Baumann, Andreas ^a   Tuerck, Dietrich ^b   Prabhu, Saileta ^c   Dickmann, Leslie ^c   Sims, Jennifer ^d  

^a BAYER PHARMA AG   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c GENENTECH INC   (United States)

^d Integrated Biologix GmbH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL DERIVATIVE; PEGYLATED PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

CELL VACUOLE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; IMMUNOREACTIVITY; KIDNEY CLEARANCE; LYSOSOME; MOLECULAR WEIGHT; NONHUMAN; OXIDATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN METABOLISM; RADIOACTIVITY; REVIEW; URINARY EXCRETION; ANIMAL; CHEMISTRY; TISSUE DISTRIBUTION;

ANIMALS; HUMANS; POLYETHYLENE GLYCOLS; PROTEINS; TISSUE DISTRIBUTION;

EID: 84908621338     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.002     Document Type: Review

References (34)

1. Veronese, F.M. and Pascut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discov. Today 10, 1451-1458
2. Lyseng-Williamson, K.A. (2011) Pegloticase: in treatment-refractory chronic gout. Drugs 71, 2179-2192
3. Yamaoka, T. et al. (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83, 601-606
4. Nakaoka, R. et al. (1997) Prolongation of the serum half-life period of superoxide dismutase by poly (ethylene glycol) modification. J. Control. Release 46, 253-261
5. Caliceti, P. and Veronese, F.M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55, 1261-1277
6. Ivens, I.A. et al. (2013) PEGylated therapeutic proteins for haemophilia treatment. A review for haemophilia caregivers. Haemophilia 19, 11-20
7. Fruijtier-Pölloth, C. (2005) Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology 214, 1-38
8. Webster, R. et al. (2007) PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab. Dispos. 35, 9-16
9. Webster, R. et al. (2009) PEG and PEG conjugate toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biological. In Pegylated Protein Drugs: Basic Science and Clinical Applications (Veronese, F.M., ed.), pp. 127-146, Birkhäuser Verlag Switzerland
10. Conover, C. et al. (1996) Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat. Artif. Cells Blood Substit. Immobil. Biotechnol. 24, 599-611
11. Bendele, A. et al. (1998) Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins. Toxicol. Sci. 42, 152-157
12. Rudmann, D.G. et al. (2013) High molecular weight polyethylene glycol cellular distribution and peg-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins. Toxicol. Pathol. 41, 970-983
13. Bannerjee, S.S. et al. (2012) Poly(ethylene glycol)-prodrugs conjugates: concept, design and applications. J. Drug Deliv. http://dx.doi.org/10.1155/2012/103973
14. Bentley, M.D. et al. (2005) Poly(ethylen) glycol conjugates of biopharmaceuticals in drug delivery. In Part VI: Advanced Application Routes for Biopharmaceuticals (Knäblein, J., ed.), p. 2022, Wiley
15. Pelham, R.W. et al. (2008) Clinical trial: single- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects. Aliment. Pharmacol. Ther. 28, 256-265
16. Shaffer, C.B. et al. (1950) The absorption and excretion of a liquid polyethylene glycol. J. Am. Pharm. Assoc. Am. Pharm. Assoc. 39, 340-344
17. Longley, C.B. et al. (2013) Biodistribution and excretion of radiolabeled 40 kDa PEG following intravenous administration in mice. J. Pharm. Sci. 102, 2362-2370
18. Elliott, V.L. et al. (2012) Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies. Mol. Pharm. 9, 1291-1301
19. Fox, M.E. et al. (2009) Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc. Chem. Res. 42, 1141-1151
20. Ruggiero, A. et al. (2010) Paradoxical glomerular filtration of carbon nanotubes. Proc. Natl. Acad. Sci. U. S. A. 107, 12369-12374
21. Parton, T. et al. (2008) Investigation of the distribution and elimination of the PEG component of certolizumab pegol in rats. J. Crohn's Colitis. Suppl. 2, 26
22. Parton, T. et al. (2009) The PEG moiety of certolizumab pegol is rapidly cleared from the blood of humans by the kidneys once it is cleaved from the Fab. Am. J. Gastroenterol. 103, S442
23. Wang, H. et al. (2012) Development of a carbon-14 labeling approach to support disposition studies with a pegylated biologic. Drug Metab. Dispos. 40, 1677-1685
24. Woodburn, K.W. et al. (2012) Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica 42, 660-670
25. Woodburn, K.W. et al. (2013) Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. Drug Metab. Dispos. 41, 774-784
26. Markovsky, E. et al. (2012) Administration, distribution, metabolism and elimination of polymer therapeutics. J. Control. Release 161, 446-460
27. Stork, R. et al. (2009) Biodistribution of a bispecific single-chain diabody and its halflife extended derivatives. J. Biol. Chem. 284, 25612-25619
28. Pietrucha, K. and Burczak, K. (1998) The effect of γ-irradiation on methoxy- poly(ethylene glycol)s in aqueous solutions. J. Bioact. Compat. Polym. 13, 279-302
29. Kronenberg, S. et al. (2013) Current challenges and opportunities in nonclinical safety testing of biologics. Drug Discov. Today 18, 1138-1143
30. Molek, J.R. and Zydney, A.L. (2006) Ultrafiltration characteristics of pegylated proteins. Biotechnol. Bioeng. 95, 474-482
31. 2O reveals a human neutrophil lifespan of 5.4 days BLOOD. 116, pp. 625-627
32. Tofts, P.S. et al. (2011) To the editor: Doubts concerning the recently reported human neutrophil lifespan of 5.4 days BLOOD. 117, pp. 6050-6052
33. Viegas, T.X. and Veronese, F.M. (2009) Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines. In Pegylated Protein Drugs: Basic Science and Clinical Applications (Veronese, F.M., ed.), pp. 273-281, Birkhäuser Verlag
34. Baumann, A. et al. (2014) New challenges and opportunities in nonclinical safety testingof biologics. Regulatory Toxicology and Pharmacology 69, 226-233